The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 07, 2026
Filed:
Jun. 07, 2022
Applicant:
Satsuma Pharmaceuticals, Inc., Durham, NC (US);
Inventors:
Shunji Haruta, Kagoshima-ken, JP;
Nikhilesh N. Singh, Mill Valley, CA (US);
John Kollins, San Francisco, CA (US);
Salvador Rico, Berkeley, CA (US);
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 31/48 (2006.01); A61K 31/522 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/22 (2006.01); A61K 47/38 (2006.01); A61P 25/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4985 (2013.01); A61K 9/0043 (2013.01); A61K 9/146 (2013.01); A61K 31/48 (2013.01); A61K 31/522 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/22 (2013.01); A61K 47/38 (2013.01);
Abstract
Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.